Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia

Hemodialysis International

Volumn 18, Issue 4, 2014, Pages 740-750

  Majoni, Sandawana William ^a,b   Ellis, Joy Anne ^a   Hall, Heather ^a   Abeyaratne, Asanga ^a   Lawton, Paul D ^c  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Erythropoiesis stimulating agents; ESA resistance; Hemodialysis; Indigenous Australians; Inflammation; Iron therapy

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRITIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ANTIANEMIC AGENT; IRON;

ADJUVANT THERAPY; ADULT; ANEMIA; ARTICLE; AUSTRALIA; CHEMOLUMINESCENCE; COHORT ANALYSIS; COULTER COUNTER; DATA BASE; DIAGNOSTIC KIT; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOASSAY; INDIGENOUS PEOPLE; INFLAMMATION; IRON THERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TRANSFERRIN BLOOD LEVEL; ADVERSE EFFECTS; BLOOD; DRUG RESISTANCE; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; OCEANIC ANCESTRY GROUP; PATHOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY;

ANEMIA; AUSTRALIA; C-REACTIVE PROTEIN; COHORT STUDIES; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMATINICS; HUMANS; INFLAMMATION; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OCEANIC ANCESTRY GROUP; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84926184950     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12173     Document Type: Article

References (44)

1. KDIGO. Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl. 2012; 2:288-291.
2. KDIGO. Chapter 2: Use of iron to treat anemia in CKD. Kidney Int Suppl. 2012; 2:292-298.
3. Horl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol. 2013; 9:291-301.
4. van der Putten K, Braam B, Jie KE, Gaillard CAJM. Mechanisms of disease: Erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008; 4:47-57.
5. Locatelli F, Altieri P, Andrulli S, etal. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: Results of a multicentre randomized and controlled trial. Nephrol Dial Transplant. 2012; 27:3594-3600.
6. Locatelli F, Andrulli S, Memoli B, etal. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006; 21:991-998.
7. Priyadarshi A, Shapiro JI. Hematology: Issues in the dialysis patient: Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial. 2006; 19:273-278.
8. Watson DS, Tozer RA. Anaemia in Yirrkala. Med J Aust. 1986; 23:S13-S15.
9. Australian Government NHMRC. Nutrition in Aboriginal and Torres Strait Islander Peoples. An Information Paper, Australia: National Health and Medical Research Council; 31 July 2000.
10. Rattanasompattikul M, Molnar MZ, Zaritsky JJ, etal. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013; 28:1936-1945.
11. Coyne D. Iron indices: What do they really mean? Kidney Int. 2006; 69(S101):S4-S8.
12. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004; 19:141-149.
13. McMahon LP, Macginley R. KHA-CARI guideline: Biochemical and haematological targets: Haemoglobin concentrations in patients using erythropoietin-stimulating agents. Nephrology. 2012; 17:17-19.
14. KDOQI. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006; 47:S16.
15. National Institute for Health and Clinical Excellence (UK). Anaemia management in people with CKD: NICE guideline. Clinical Guideline 114(CG114). 2011; 3-37.
16. Guidelines EBP. Appendix B: Assessment of iron stores and functional iron deficiency. Nephrol Dial Transplant. 2004; 19(Suppl 2):ii39-ii41.
17. Levin A, Hemmelgarn B, Culleton B, etal. Guidelines for the management of chronic kidney disease. Can Med Assoc J. 2008; 179:1154-1162.
18. Coyne DW, Kapoian T, Suki W, etal. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18:975-984.
19. Kapoian T, O'Mara NB, Singh AK, etal. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008; 19:372-379.
20. Suranyi M, Bannister KM. Practical experience with the renal anaemia management database. Nephrology. 2002; 7:S7-S11.
21. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: Recommendations from clinical studies. Pharmacotherapy. 2002; 22(9 Part 2):160S-165.
22. Schneider A, Schneider M, Scharnagl H, Jardine A, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrol. 2013; 14:67.
23. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008; 111:S75-S81.
24. Chung S, Song HC, Shin SJ, etal. Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis. Hemodial Int. 2012; 16:181-187.
25. Roy CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010; 2010:276-280.
26. Weiss G, Goodnough LT. Anemia of chronic disease. NEJM. 2005; 352:1011-1023.
27. Mudge D, Johnson D, Hawley C, etal. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol. 2011; 12:20.
28. Pasricha SR, Flecknoe-Brown SC, Allen KJ, etal. Diagnosis and management of iron deficiency anaemia: A clinical update. Med J Aust. 2010; 193:525-532.
29. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients1. Kidney Int. 2001; 60:2406-2411.
30. Chiang WC, Tsai TJ, Chen YM, Lin SL, Hsieh BS. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol. 2002; 58:363-369.
31. Tessitore N, Solero GP, Lippi G, etal. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001; 16:1416-1423.
32. Ritchie B, McNeil Y, Brewster DR. Soluble transferrin receptor in Aboriginal children with a high prevalence of iron deficiency and infection. Trop Med Int Health. 2004; 9:96-105.
33. Cherian S, Forbes DA, Cook AG, etal. An insight into the relationships between hepcidin, anemia, infections and inflammatory cytokines in pediatric refugees: A cross-sectional study. PLoS ONE. 2008; 3:e4030.
34. Coyne DW. Hepcidin: Clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011; 80:240-244.
35. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009; 4:1384-1387.
36. Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5:1681-1689.
37. Eleftheriadis T, Pissas G, Remoundou M, etal. Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin. Int Urol Nephrol. 2014; 46:161-167.
38. Tessitore N, Girelli D, Campostrini N, etal. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010; 25:3996-4002.
39. van der Weerd NC, Grooteman MP, Bots ML, etal. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS ONE. 2012; 7:13.
40. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16:3070-3080.
41. Feldman HI, Joffe M, Robinson B, etal. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004; 15:1623-1632.
42. Feldman HI, Santanna J, Guo W, etal. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol. 2002; 13:734-744.
43. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006; 1(Suppl 1):S9-S18.
44. Claes J, Ellis J-AL, Rettie F, Butcher B, Bradley J. Are C-reactive protein and ferritin levels being overlooked in indigenous Australians with chronic kidney disease? J Ren Care. 2013; 39:176-181.